세계 당뇨병 치료제 시장 - 점유율 분석, 산업 동향과 통계, 성장 예측(2024-2029년)

The Diabetes Care Drugs Market size is estimated at USD 87.53 billion in 2024, and is expected to reach USD 104.01 billion by 2029, growing at a CAGR of 3.51% during the forecast period (2024-2029).

The diabetes care drugs market experienced a significant impact due to the COVID-19 pandemic. This global health crisis shed light on the potential for advancements in diabetes care through virtual consultations between healthcare professionals and individuals with diabetes, as well as the utilization of diabetes technology. The management of the crisis led to an unprecedented interest in remote care from both patients and providers, resulting in the removal of various regulatory barriers that had long been in place. As an example, the US Food and Drug Administration permitted the use of personal blood glucose meters and continuous glucose monitoring devices in hospitals during the pandemic. The high prevalence of diabetes among individuals hospitalized with COVID-19 infection, coupled with the understanding that better glycemic control could enhance outcomes and reduce hospital stays for patients with SARS-CoV-2, emphasized the significance of diabetes care devices.

Diabetes is a chronic, life-threatening disease with no known cure. As per the World Health Organization, there are over 400 million people with diabetes across the world, and its treatment constitutes around 12% of the total healthcare expenditure on a global scale. It has emerged as a global epidemic and afflicted millions worldwide.

The significant growth in the market can be attributed to factors such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. Currently, about 10% of all diabetes cases are Type-1, and the remaining are Type-2.

As of 2021, North America accounted for a major share of the market, followed by Asia-Pacific. The increase in the number of diabetes patients is primarily due to increasing obesity among people caused by unhealthy diets and sedentary lifestyles. The market in Asia-Pacific is mainly driven by increasing demand for diabetes drugs from China and India. Currently, China has over 129 million diabetes patients, while the number of diabetes patients in India is expected to reach 82 million by 2027.

Based on drugs, the insulin segment holds a significant share of the market. Over 100 million people around the world need insulin, including all the people who have Type-1 diabetes and between 10% and 25% of people with Type-2 diabetes. Production of insulin is very complex, and there are very few companies in the market that manufacture insulin. Due to this, there is high competition between these manufacturers, who always strive to meet the patient's needs to supply the best-quality insulin.

Diabetes Drug Market Trends

Insulin Drugs is Having the Highest Market Share in current year

• The insulin segment is expected to increase with a CAGR of over 3% during the forecast period, mainly due to the demand from the Type-1 diabetes population, which was more than 58 million by the end of the forecast year.
• According to the International Diabetes Federation, diabetes patients spent USD 966 billion in 2021, of which Type-1 diabetes patients spent a major chunk on insulin drugs. Few Type-2 diabetes patients also depend on insulin. Although only 10% of the diabetes population is Type-1, their intake of insulin is higher in them.
• Demand for insulin or diabetes treatment drugs is driven by an increase in awareness about the benefits of insulin for diabetes patients, especially in emerging economies. Other factors, such as rapid development in insulin delivery systems, drug and analog development by major companies, and the rise in the geriatric and obese population, may fuel the growth of the insulin market.
• Patients with Type 2 diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia.
• Although insulin has been used in the treatment of diabetes across the world for over 90 years, more than half of the population in need of insulin today still cannot afford or access it. People with Type-1 diabetes need insulin therapy, and the treatment focuses on managing blood sugar levels with insulin, diet, and lifestyle to prevent complications. Traditional biosimilars were mostly the regular human insulin biosimilars that were manufactured copies of previously approved biopharmaceuticals, which are no longer under patent protection, by any insulin pharma companies.

North America is Expected to Dominate the Diabetes Drugs Market.

• North America dominates the global insulin therapeutics market due to the region's high prevalence of diabetes, attributed to sedentary lifestyles and the introduction of new drugs. Within North America, the United States is expected to experience significant growth in the forecast period. Factors like the escalating prevalence of obesity and an increasing focus on diabetes care awareness fuel this growth.
• The United States remains the largest market for insulin drugs in North America, primarily driven by substantial demand. The American Diabetes Association, a prominent agency dedicated to diabetes control in the U.S., aims to enhance public awareness, funding vital research and development operations for managing, curing, and preventing diabetes.
• Contributing to North America's revenue, the United States holds a major share, accounting for 92% of the current year's revenue, owing to its significant diabetic population. Annually, approximately 1.75 million Americans receive a diabetes diagnosis, with the country also facing a high prevalence of obesity, a leading cause of Type 2 diabetes.
• The traditional human insulin drugs market is anticipated to grow due to its economic affordability for patients. Among these drugs, Humulin leads in market share, closely followed by Novolin. Notably, there currently need to be generic competitors for the traditional human insulin drugs market in the United States. These factors collectively are expected to drive market growth over the forecast period.

Diabetes Drug Industry Overview

The diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market are dominated by a few major players in diabetes pharamcetutical companies, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definitions
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
• 4.3 Market Restraints
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Bargaining Power of Suppliers
  • 4.4.2 Bargaining Power of Consumers
  • 4.4.3 Threat of New Entrants
  • 4.4.4 Threat of Substitute Products and Services
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Drugs
  • 5.1.1 Oral Anti-diabetic drugs
    • 5.1.1.1 Biguanides
    • 5.1.1.1.1 Metformin
    • 5.1.1.2 Alpha-glucosidase Inhibitors
    • 5.1.1.3 Dopamine -D2 Receptor Agonist
    • 5.1.1.3.1 Cycloset (Bromocriptin)
    • 5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
    • 5.1.1.4.1 Invokana (Canagliflozin)
    • 5.1.1.4.2 Jardiance (Empagliflozin)
    • 5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    • 5.1.1.4.4 Suglat (Ipragliflozin)
    • 5.1.1.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    • 5.1.1.5.1 Januvia (Sitagliptin)
    • 5.1.1.5.2 Onglyza (Saxagliptin)
    • 5.1.1.5.3 Tradjenta (Linagliptin)
    • 5.1.1.5.4 Vipidia/Nesina (Alogliptin)
    • 5.1.1.5.5 Galvus (Vildagliptin)
    • 5.1.1.6 Sulfonylureas
    • 5.1.1.7 Meglitinides
  • 5.1.2 Insulin
    • 5.1.2.1 Basal or Long-acting Insulin
    • 5.1.2.1.1 Lantus (Insulin Glargine)
    • 5.1.2.1.2 Levemir (Insulin Detemir)
    • 5.1.2.1.3 Toujeo (Insulin Glargine)
    • 5.1.2.1.4 Tresiba (Insulin Degludec)
    • 5.1.2.1.5 Basaglar (Insulin Glargine)
    • 5.1.2.2 Bolus or Fast-acting Insulin
    • 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
    • 5.1.2.2.2 Humalog (Insulin Lispro)
    • 5.1.2.2.3 Apidra (Insulin Glulisine)
    • 5.1.2.3 Traditional Human Insulin
    • 5.1.2.3.1 Novolin/Actrapid/Insulatard
    • 5.1.2.3.2 Humulin
    • 5.1.2.3.3 Insuman
    • 5.1.2.4 Biosimilar Insulin
    • 5.1.2.4.1 Insulin Glargine Biosimilars
    • 5.1.2.4.2 Human Insulin Biosimilars
  • 5.1.3 Non-insulin Injectable Drug
    • 5.1.3.1 GLP-1 Receptor Agonists
    • 5.1.3.1.1 Victoza (Liraglutide)
    • 5.1.3.1.2 Byetta (Exenatide)
    • 5.1.3.1.3 Bydureon (Exenatide)
    • 5.1.3.1.4 Trulicity (Dulaglutide)
    • 5.1.3.1.5 Lyxumia (Lixisenatide)
    • 5.1.3.2 Amylin Analogue
    • 5.1.3.2.1 Symlin (Pramlintide)
  • 5.1.4 Combination Drug
    • 5.1.4.1 Combination Insulin
    • 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
    • 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    • 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
    • 5.1.4.2 Oral Combination
    • 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
• 5.2 By Route of Administration
  • 5.2.1 Oral
  • 5.2.2 Subcutaneous
  • 5.2.3 Intravenous
• 5.3 By Distribution Channel
  • 5.3.1 Online
  • 5.3.2 Offline
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Rest of North America
  • 5.4.2 Europe
    • 5.4.2.1 France
    • 5.4.2.2 Germany
    • 5.4.2.3 Italy
    • 5.4.2.4 Spain
    • 5.4.2.5 United Kingdom
    • 5.4.2.6 Russia
    • 5.4.2.7 Rest of Europe
  • 5.4.3 Latin America
    • 5.4.3.1 Mexico
    • 5.4.3.2 Brazil
    • 5.4.3.3 Rest of Latin America
  • 5.4.4 Asia-Pacific
    • 5.4.4.1 Japan
    • 5.4.4.2 South Korea
    • 5.4.4.3 China
    • 5.4.4.4 India
    • 5.4.4.5 Australia
    • 5.4.4.6 Vietnam
    • 5.4.4.7 Malaysia
    • 5.4.4.8 Indonesia
    • 5.4.4.9 Philippines
    • 5.4.4.10 Thailand
    • 5.4.4.11 Rest of Asia-Pacific
  • 5.4.5 Middle-East and Africa
    • 5.4.5.1 Saudi Arabia
    • 5.4.5.2 Iran
    • 5.4.5.3 Egypt
    • 5.4.5.4 Oman
    • 5.4.5.5 South Africa
    • 5.4.5.6 Rest of Middle-East and Africa

6 MARKET INDICATORS

• 6.1 Type-1 Diabetes Population
• 6.2 Type-2 Diabetes Population

7 COMPETITIVE LANDSCAPE

• 7.1 Company Profiles
  • 7.1.1 Novo Nordisk
  • 7.1.2 Sanofi
  • 7.1.3 Eli Lilly and Company
  • 7.1.4 Biocon
  • 7.1.5 AstraZeneca
  • 7.1.6 Bristol Myers Squibb
  • 7.1.7 Boehringer Ingelheim
  • 7.1.8 Mylan
  • 7.1.9 Pfizer
  • 7.1.10 Johnson & Johnson
  • 7.1.11 Merck & Co.
  • 7.1.12 Novartis
  • 7.1.13 Astellas Pharma
  • 7.1.14 Teva Pharmaceuticals
• 7.2 Company Share Analysis
  • 7.2.1 Insulin Drugs
    • 7.2.1.1 Novo Nordisk
    • 7.2.1.2 Sanofi
    • 7.2.1.3 Eli Lilly and Company
    • 7.2.1.4 Others

8 MARKET OPPORTUNITIES AND FUTURE TRENDS